Relationship between adiponectin and copeptin levels with long-term cardiovascular mortality in ST-segment elevation myocardial infarction after percutaneous coronary intervention

Basit Öğe Kaydı
dc.authoridOzcan, Kazim Serhan/0000-0002-5321-442X
dc.authorwosidaltay, servet/C-1387-2018
dc.authorwosidOzcan, Kazim Serhan/O-3365-2018
dc.contributor.authorCabbar, Ayca Turer
dc.contributor.authorYildirim, Ersin
dc.contributor.authorCalbayram, Ozge Guzelburc
dc.contributor.authorSimsek, Mustafa A.
dc.contributor.authorAltay, Servet
dc.contributor.authorOzcan, Kazim S.
dc.contributor.authorDegertekin, M. Muzaffer
dc.date.accessioned2024-06-12T11:15:43Z
dc.date.available2024-06-12T11:15:43Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to determine adiponectin and copeptin levels that might be prognostic for cardiovascular mortality (CvsM) in ST-segment elevation myocardial infarction (STEMI) patients who had percutaneous coronary intervention (PCI).Methods: Patients who underwent PCI between November 2010 and April 2011 were enrolled and followed for more than eight years. The baseline, demographic and angiographic findings, in-hospital follow up, laboratory results including adiponectin and copeptin levels, and echocardiographic data of the patients were evaluated.Results: There were 78 males and 20 females. The CvsM rate was 26.66% at 112 months of follow up. Some factors were significantly related to CvsM and adiponectin level was an independent predictor of mortality. A cut-off value of >= 8 950 ng/ml for adiponectin and >= 7.41 ng/ml for copeptin was related to a 3.01-and 2.83-times higher CvsM risk, respectively.Conclusion: Adiponectin level was a predictor for CvsM. Higher levels of adiponectin and copeptin could predict a higher risk of CvsM in STEMI patients.en_US
dc.identifier.doi10.5830/CVJA-2023-046
dc.identifier.issn1995-1892
dc.identifier.issn1680-0745
dc.identifier.pmid37906447en_US
dc.identifier.urihttps://doi.org/10.5830/CVJA-2023-046
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24047
dc.identifier.wosWOS:001084418300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinics Cardive Publ Pty Ltden_US
dc.relation.ispartofCardiovascular Journal Of Africaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectST-Segment Elevation Myocardial Infarctionen_US
dc.subjectMortalityen_US
dc.subjectAdiponectinen_US
dc.subjectCopeptinen_US
dc.subjectAll-Cause Mortalityen_US
dc.subjectPlasma Adiponectinen_US
dc.subjectHeart-Failureen_US
dc.subjectSerum Adiponectinen_US
dc.subjectPrognostic-Factoren_US
dc.subjectPrimary Pcien_US
dc.subjectAssociationen_US
dc.subjectEventsen_US
dc.subjectStemien_US
dc.subjectPredictionen_US
dc.titleRelationship between adiponectin and copeptin levels with long-term cardiovascular mortality in ST-segment elevation myocardial infarction after percutaneous coronary interventionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu